The Future of Pediatric Pneumococcal Vaccines

Musey discussed any gaps and limitations that researchers should focus on in future studies and what he hopes to see for the future of pneumococcal vaccines and this disease.

Pharmacy Times spoke with Luwy Musey, executive director in clinical research on biologics and vaccines at Merck, about the results of two Phase 3 pediatric studies in pneumococcal disease presented at the IDWeek 2021 conference.

Musey discussed any gaps and limitations that researchers should focus on in future studies and what he hopes to see for the future of pneumococcal vaccines and this disease.

Comments are closed.